Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study
dc.contributor.author | Hutchings, Martin | |
dc.contributor.author | Radford, John | |
dc.contributor.author | Ansell, Stephen M. | |
dc.contributor.author | Illés, Árpád | |
dc.contributor.author | Sureda, Anna | |
dc.contributor.author | Connors, Joseph M. | |
dc.contributor.author | Sýkorová, Alice | |
dc.contributor.author | Shibayama, Hirohiko | |
dc.contributor.author | Abramson, Jeremy S. | |
dc.contributor.author | Chua, Neil S. | |
dc.contributor.author | Friedberg, Jonathan W. | |
dc.contributor.author | Kořen, Jan | |
dc.contributor.author | LaCasce, Ann Steward | |
dc.contributor.author | Molina, Lysiane | |
dc.contributor.author | Engley, Gerald | |
dc.contributor.author | Fenton, Keenan | |
dc.contributor.author | Jolin, Hina A. | |
dc.contributor.author | Liu, Rachael | |
dc.contributor.author | Gautam, Ashish | |
dc.contributor.author | Gallamini, Andrea | |
dc.date.accessioned | 2021-04-19T08:04:31Z | |
dc.date.available | 2021-04-19T08:04:31Z | |
dc.date.issued | 2021 | |
dc.date.oa | 2021-04-19 | |
dc.date.pasync | 2022-03-23T01:30:22Z | |
dc.date.updated | 2022-03-23T01:30:22Z | |
dc.description.corrector | LB | |
dc.identifier.citation | Hematological Oncology. -39 : 2 (2021), p. 185-195. -Hematol. Oncol. - 0278-0232 | |
dc.identifier.doi | http://dx.doi.org/10.1002/hon.2838 | |
dc.identifier.issn | 0278-0232 | |
dc.identifier.opac | http://webpac.lib.unideb.hu:8082/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM093521 | |
dc.identifier.uri | http://hdl.handle.net/2437/306129 | |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1002/hon.2838 | |
dc.language | eng | |
dc.rights.access | open access article | |
dc.subject.mab | Orvostudományok | |
dc.subject.mab | Klinikai orvostudományok | |
dc.title | Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study | |
dc.type | idegen nyelvű folyóiratközlemény külföldi lapban |
Fájlok
Eredeti köteg (ORIGINAL bundle)
1 - 1 (Összesen 1)
Nem elérhető
- Név:
- FILE_UP_1_Brentuximab vedotin plus doxorubicin.pdf
- Méret:
- 4.63 MB
- Formátum:
- Adobe Portable Document Format
- Leírás:
- kiadói változat